Evolving Strategies for Target Selection for Antibody-Drug Conjugates (original) (raw)

• Krall N, Scheuerman J, Neri D. Small targeted cytotoxics: current state and promises from DNA-encoded chemical libraries. Angew Chem Int Ed. 2013;52:1384–402.
  Article CAS Google Scholar
• Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. NEJM. 2012;367(19):1783–91.
  Article CAS PubMed Google Scholar
• Hurvitz SA, Dirix L, Kocsis J, Bianchi GV, Lu J, Vinholes J, et al. Phase II randomized study of Trastuzumab emtansine versus Trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer. J Clin Oncol. 2013;31(9):1157–63.
  Article CAS PubMed Google Scholar
• Mullard A. Maturing antibody-drug conjugate pipeline hits 30. Nat Rev Drug Discov. 2013;12:329–32.
  Article CAS PubMed Google Scholar
• Sapra P, Hooper AT, O’Donnell CJ, Gerber HP. Investigational antibody drug conjugates for solid tumors. Expert Opin Investig drugs. 2011;20:1131–49.
  Article CAS PubMed Google Scholar
• Burris HA, Gordon MS, Gerber DE, Spigel DR, Mendelson DS, Schiller JH, et al. A Phase 1 study of DNIB0600A, an Antibody-Drug Conjugate (ADC) Targeting NaPi2b, in Patients (Pts) with Non-Small Cell Lung Cancer (NSCLC) or Platinum-Resistant Ovarian Cancer (OC). J Clin Oncol 2014, 32:5s Supplement, Abstract 2504.
• Sapra P, Damelin M, Dijoseph J, Marquette K, Geles KG, Golas J, et al. Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells. Mol Cancer Ther. 2013;12(1):38–47. doi:10.1158/1535-7163.MCT-12-0603.
  Article CAS PubMed Google Scholar
• Cancer Genome Atlas Research Network, Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, et al. The cancer genome atlas pan-cancer analysis project. Nat Genet. 2013;45(10):1113–20. doi:10.1038/ng.2764.
  Article PubMed Central Google Scholar
• GTEx Consortium. The genotype-tissue expression (GTEx) project. Nat Genet. 2013;45:580–5.
  Article Google Scholar
• Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet. 2009;10(1):57–63.
  Article PubMed Central CAS PubMed Google Scholar
• Schwanhausser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, et al. Global quantification of mammalian gene expression control. Nature. 2011;473(7347):337–42.
  Article PubMed Google Scholar
• Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483(7391):603–7. doi:10.1038/nature11003. Erratum in: Nature. 2012 Dec 13;492(7428):290.
  Article PubMed Central CAS PubMed Google Scholar
• Polson AG, Yu SF, Elkins K, Zheng B, Clark S, Ingle GS, et al. Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma. Blood. 2007;110:616–23. doi:10.1182/blood-2007-01-066704.
  Article CAS PubMed Google Scholar
• Gerber DE, Infante JR, Gordon MS, Schiller JH, Spigel D, Wang Y et al. Safety, Pharmacokinetics, and Activity of the Anti-NaPi2b Antibody-Drug Conjugate DNIB0600A: A Phase I Study in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer. IASLC World Lung, Sydney, Australia, Oct 27–30, 2013.
• Kim MS, Pinto SM, Getnet D, Nirujogi RS, Manda SS, Chaerkady R, et al. A draft map of the human proteome. Nature. 2014;509:575–81.
  Article PubMed Central CAS PubMed Google Scholar
• Strassberger V, Trussel S, Fugmann T, Neri D, Roesli C. A novel reactive ester derivative of biotin with reduced membrane permeability for in vivo biotinylation experiments. Proteomics. 2010;10(19):3544–8.
  Article CAS PubMed Google Scholar
• Zhang H, Li XJ, Martin DB, Aebersold R. Identification and quantification of N-linked glycoproteins using hydrazine chemistry, stable isotope labeling and mass spectrometry. Nat Biotechnol. 2003;21(6):660–6.
  Article CAS PubMed Google Scholar
• Fujiki Y, Hubbard AL, Fowler S, Lazarow PB. Isolation of intracellular membranes by means of sodium carbonate treatment: application to endoplasmic reticulum. J Cell Biol. 1982;93(1):97–102.
  Article CAS PubMed Google Scholar
• Simons K, Ikonen E. Functional rafts in cell membranes. Nature. 1997;387:569–72.
  Article CAS PubMed Google Scholar
• Beck M, Schmidt A, Malmstroem J, Claassen M, Ori A, Szymborksa A, et al. The quantitative proteome of a human cell line. Mol Syst Biol. 2011;7:549.
  Article PubMed Central PubMed Google Scholar
• Lu P, Vogel C, Wang R, Yao X, Marcotte M. Absolute protein expression profiling estimates the relative contributions of transcriptional and translational regulation. Nat Biotechnol. 2007;25(1):117–24.
  Article CAS PubMed Google Scholar
• Danila DC, Szmuelwitz RZ, Baron AD, Higano CS, Scher HI, Morris MJ, et al. A Phase I Study of DSTP3086S, an Antibody-Drug Conjugate (ADC) targeting STEAP-1, in Patients (Pts) with Metastatic Castration-Resitant Prostate Cancer (CRPC). J Clin Oncol 2014; 32:5s Suppl; Abstract 5024.
• Burris HA, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, et al. Phase II study of the antibody drug conjugate Trastuzumab-DM1 for the treatment of human epidermal growth factor receptor (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2011;29(4):298–405.
  Article Google Scholar
• Krop IE, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, et al. A phase II study of Trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer Who were previously treated with Trastuzumab, Lapatinib, an anthracycline, a taxane and capecitabine. J Clin Oncol. 2012;30(26):3234–41.
  Article CAS PubMed Google Scholar
• Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707–12.
  Article CAS PubMed Google Scholar
• Dijoseph JF, Dougher MM, Armellino DC, Evans DY, Damle NK. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia. 2007;21(11):2240–5.
  Article CAS PubMed Google Scholar
• Fromm JR, McEarchern JA, Kennedy D, Thomas A, Shustov AR, Gopal AK. Clinical binding properties, internalization kinetics, and clinicopathologic activity of brentuximab vedotin: an antibody-drug conjugate for CD30-positive lymphoid neoplasms. Clin Lymhoma Myeloma Leuk. 2012;12(4):280–3.
  Article CAS Google Scholar
• Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30(18):2183–9. doi:10.1200/JCO.2011.38.0410.
  Article PubMed Central CAS PubMed Google Scholar
• Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190–6. doi:10.1200/JCO.2011.38.0402.
  Article CAS PubMed Google Scholar
• Tijink BM, Buter J, de Bree R, Giaccone G, Lang MS, Staab A, et al. A phase IDose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res. 2006;12(20):6064–72. doi:10.1158/1078-0432.CCR-06-0910.
  Article CAS PubMed Google Scholar
• Boswell CA, Mundo EE, Firestein R, Zhang C, Mao W, Gill H, et al. An integrated approach toidentify normal tissue expression of targets for antibody-drug conjugates: case study of TENB2. Br J Pharm. 2013;168:445–57. doi:10.1111/j.1476-5381.2012.02138.x.
  Article CAS Google Scholar
• Perrino E, Steiner M, Krall N, Bernardes GJ, Pretto F, Casi G, et al. Curative properties of noninternalizing antibody–drug conjugates based on maytansinoids. Cancer Res. 2014;74(9):2569–78. doi:10.1158/0008-5472.CAN-13-2990.
  Article CAS PubMed Google Scholar
• Ingle GS, Chan P, Elliott JM, Chang WS, Koeppen H, Stephan JP, et al. High CD21 expression inhibits internalization of anti-CD19 antibodies and cytotoxicity of an anti-CD19-drug conjugate. Br J Haematol. 2008;140(1):46–58.
  PubMed Central CAS PubMed Google Scholar
• Shi F, Sottile J. Caveolin-1-dependent 1 integrin endocytosis is a critical regulator of fibronectin turnover. J Cell Sci. 2008;121:2360–71.
  Article PubMed Central CAS PubMed Google Scholar
• Muro S, Mateescu M, Gajewski C, Robinson M, Muzykantov VR, Koval M. Control of intracellular trafficking of ICAM-1-targeted nanocarriers by endothelial Na+/H+ exchanger proteins. Am J Physiol Lung Cell Mol Physiol. 2006;290:L809–17. doi:10.1152/ajplung.00311.2005.
  Article CAS PubMed Google Scholar
• Du J, Chen X, Liang X, Zhang G, Xu J, He L, et al. Integrin activation and internalization on soft ECM as a mechanism of induction of stem cell differentiation by ECM elasticity. Proc Natl Acad Sci. 2011;108(23):9466–71.
  Article PubMed Central CAS PubMed Google Scholar
• Teicher BA. Antibody-drug conjugate targets. Curr Cancer Drug Targets. 2009;9(8):982–1004.
  Article CAS PubMed Google Scholar
• Golfier S, Kopitz C, Kahnert A, Heisler I, Schatz CA, Stelte-Ludwig B, et al. Anetumab ravtansine - a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect. Mol Cancer Ther. 2014;13(6):1537–48.
  Article CAS PubMed Google Scholar
• Govindan SV, Cardillo TM, Moon SJ, Hansen HJ, Goldenberg DM. CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates. Clin Cancer Res. 2009;15(19):6052–61. doi:10.1158/1078-0432.CCR-09-0586.
  Article PubMed Central CAS PubMed Google Scholar
• Kelly RK, Olson DL, Sun Y, Wen D, Wortham KA, Antognetti G, et al. An antibody-cytotoxic conjugate, BIIB015, is a new targeted therapy for Cripto positive tumours. Eur J Cancer. 2011;47(11):1736–46. doi:10.1016/j.ejca.2011.02.023.
  Article CAS PubMed Google Scholar
• Sausville E, LoRusso P, Quinn M, Forman K, Leamon C, Morganstern D, et al. A phase I study of EC145 administered weeks 1 and 3 of a 4-week cycle in patients with refractory solid tumors. J Clin Oncol. 2007;25(18S):2577.
  Google Scholar
• Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007;26(45):6469–87.
  Article PubMed Central CAS PubMed Google Scholar
• Phillips GD, Fields CT, Li G, Dowbenko D, Schaefer G, Miller K, et al. Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy. Clin Cancer Res. 2014;20(2):456–68. doi:10.1158/1078-0432.CCR-13-0358.
  Article CAS PubMed Google Scholar
• Gwin WR, Spector NL. Pertuzumab protects the achilles’ heel of trastuzumab–emtansine. Clin Cancer Res. 2014;20(2):278–80. doi:10.1158/1078-0432.CCR-13-2626.
  Article CAS PubMed Google Scholar
• Tan X, Lu B, Jin G, Wang F, Myers J, Musto S, et al. Antibody-drug conjugates with modified linker-payloads overcome resistance to a trastuzumab-maytansinoid conjugate in multiple cultured tumor cell models. AACR Annual Meeting 2014, Abstract #1830.
• Doronina SO, Mendelsohn BA, Bovee TD, Cerveny CG, Alley SC, Meyer DL, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem. 2006;17:114–24.
  Article CAS PubMed Google Scholar
• Sapra P, Stein R, Pickett J, Qu Z, Govindan SV, Cardillo TM, et al. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. Clin Cancer Res. 2005;11(14):5257–64.
  Article CAS PubMed Google Scholar
• Laurent-Puig P, Lievre A, Blons H. Mutations and response to epidermal growth factor receptor inhibitors. Clin Cancer Res. 2009;15(4):1133–9. doi:10.1158/1078-0432.CCR-08-0905.
  Article CAS PubMed Google Scholar
• Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov. 2009;8(10):806–23. doi:10.1038/nrd2137.
  Article CAS PubMed Google Scholar
• Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer and cancer stem cells. Nature. 2001;414:105–11.
  Article CAS PubMed Google Scholar
• Visvader JE, Lindeman GJ. Cancer stem cells in solid tumors: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008;8:755–68.
  Article CAS PubMed Google Scholar
• Gerber HP, Senter PD, Grewal IS. Antibody drug-conjugates targeting the tumor vasculature: current and future developments. mAbs. 2009;1(3):247–53.
  Article PubMed Central PubMed Google Scholar
• Ostermann E, Garin-Chesa P, Heider KH, Kalat M, Lamche H, Puri C, et al. Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts. Clin Cancer Res. 2008;14(14):4584–92. doi:10.1158/1078-0432.CCR-07-5211.
  Article CAS PubMed Google Scholar
• Bernardes GJ, Casi G, Trussel S, Hartmann I, Schwager K, Scheuermann J, et al. A traceless vascular-targeting antibody-drug conjugate for cancer therapy. Angew Chem Int Ed Engl. 2012;51(4):941–4.
  Article CAS PubMed Google Scholar
• Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999;59(13):3192–8.
  CAS PubMed Google Scholar
• Gutbrodt KL, Schliemann C, Giovannoni L, Frey K, Pabst T, Klapper W, et al. Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia. Sci Transl Med. 2013;5(201):201ra118. doi:10.1126/scitranslmed.3006221.
  Article PubMed Google Scholar
• Sauer S, Erba PA, Petrini M, Menrad A, Giovannoni L, Grana C, et al. Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood. 2009;113(10):2265–74. doi:10.1182/blood-2008-06-160416.
  Article CAS PubMed Google Scholar
• Chen Y, Clark S, Wong T, Chen Y, Chen Y, Dennis MS, et al. Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, Are highly efficacious in animal tumor models. Cancer Res. 2007;67:4924–32.
  Article CAS PubMed Google Scholar
• Pak Y, Zhang Y, Pastan I, Lee B. Antigen shedding May improve efficiencies for delivery of antibody-based anticancer agents in solid tumors. Cancer Res. 2012;72:3143–52.
  Article PubMed Central CAS PubMed Google Scholar
• Shih SC, Sloper-Mould KE, Hicke L. Monoubiquitin carries a novel internalization signal that is appended to activated receptors. EMBO J. 2000;19:187–98.
  Article PubMed Central CAS PubMed Google Scholar
• Wright Jr GL, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology. 1996;48(2):326–34.
  Article PubMed Google Scholar
• Ma D, Hopf CE, Malewicz AD, Donovan GP, Senter PD, Goeckeler WF, et al. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen. Clin Cancer Res. 2006;12(8):2591–6.
  Article CAS PubMed Google Scholar
• Bander NH. Antibody-drug conjugate target selection: critical factors. Methods Mol Biol. 2013;1045:29–40.
  Article PubMed Google Scholar
• Amato RJ, Stepankiw M. Evaluation of MVA-5 T4 as a novel immunotherapeutic vaccine in colorectal, renal and prostate cancer. Future Oncol. 2012;8(3):231–7. doi:10.2217/fon.12.7.
  Article CAS PubMed Google Scholar
• Forsberg G, Skartved NJ, Wallén-Ohman M, Nyhlén HC, Behm K, Hedlund G, et al. Naptumomab estafenatox, an engineered antibody-superantigen fusion protein with low toxicity and reduced antigenicity. J Immunother. 2010;33(5):492–9. doi:10.1097/CJI.0b013e3181d75820.
  Article PubMed Google Scholar
• Hole N, Stern PL. A 72 kD trophoblast glycoprotein defined by a monoclonal antibody. Br J Cancer. 1988;57:239–46.
  Article PubMed Central CAS PubMed Google Scholar
• Hole N, Stern PL. Isolation and characterization of 5T4, a tumour-associated antigen. Int J Cancer. 1990;45:179–84.
  Article CAS PubMed Google Scholar
• Barrow KM, Ward CM, Rutter J, Ali S, Stern PL. Embryonic expression of murine 5T4 oncofoetal antigen is associated with morphogenetic events at implantation and in developing epithelia. Dev Dyn. 2005;233(4):1535–45.
  Article CAS PubMed Google Scholar
• Damelin M, Geles KG, Follettie MT, Yuan P, Baxter M, Golas J, et al. Delineation of a cellular hierarchy in lung cancer reveals an oncofetal antigen expressed on tumor-initiating cells. Cancer Res. 2011;71:4236–46.
  Article CAS PubMed Google Scholar
• Naganuma H, Kono K, Mori Y, Takayoshi S, Stern PL, Tasaka K, et al. Oncofetal antigen 5T4 expression as a prognostic factor in patients with gastric cancer. Anticancer Res. 2002;22(2B):1033–8.
  CAS PubMed Google Scholar
• Starzynska T, Marsh PJ, Schofield PF, Roberts SA, Myers KA, Stern PL. Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma. Br J Cancer. 1994;69(5):899–902.
  Article PubMed Central CAS PubMed Google Scholar
• Wrigley E, McGown AT, Rennison J, Swindell R, Crowther D, Starzynska T, et al. 5T4 oncofetal antigen expression in ovarian carcinoma. Int J Gynecol Cancer. 1995;5(4):269–74.
  Article PubMed Google Scholar
• Eastham AM, Spencer H, Soncin F, Ritson S, Merry CL, Stern PL, et al. Epithelial-mesenchymal transition events during human embryonic stem cell differentiation. Cancer Res. 2007;67(23):11254–62.
  Article CAS PubMed Google Scholar
• Spencer HL, Eastham AM, Merry CL, Southgate TD, Perez-Campo F, Soncin F, et al. E-cadherin inhibits cell surface localization of the pro-migratory 5T4 oncofetal antigen in mouse embryonic stem cells. Mol Biol Cell. 2007;18(8):2838–51.
  Article PubMed Central CAS PubMed Google Scholar
• Carsberg CJ, Myers KA, Stern PL. Metastasis-associated 5T4 antigen disrupts cell-cell contacts and induces cellular motility in epithelial cells. Int J Cancer. 1996;68(1):84–92.
  Article CAS PubMed Google Scholar
• Kagermeier-Schenk B, Wehner D, Ozhan-Kizil G, Yamamoto H, Li J, Kirchner K, et al. Waif1/5T4 inhibits Wnt/β-catenin signaling and activates noncanonical Wnt pathways by modifying LRP6 subcellular localization. Dev Cell. 2011;21(6):1129–43. doi:10.1016/j.devcel.2011.10.015.
  Article CAS PubMed Google Scholar
• Gromova P, Ralea S, Lefort A, Libert F, Rubin BP, Erneux C, et al. Kit K641E oncogene up-regulates Sprouty homolog 4 and trophoblast glycoprotein in interstitial cells of Cajal in a murine model of gastrointestinal stromal tumours. J Cell Mol Med. 2009;13(8A):1536–48. doi:10.1111/j.1582-4934.2009.00768.x.
  Article PubMed Central CAS PubMed Google Scholar
• Southgate TD, McGinn OJ, Castro FV, Rutkowski AJ, Al-Muftah M, Marinov G, et al. CXCR4 mediated chemotaxis is regulated by 5T4 oncofetal glycoprotein in mouse embryonic cells. PLoS ONE. 2010;5(4):e9982. doi:10.1371/journal.pone.0009982.
  Article PubMed Central PubMed Google Scholar
• McGinn OJ, Marinov G, Sawan S, Stern PL. CXCL12 receptor preference, signal transduction, biological response and the expression of 5T4 oncofoetal glycoprotein. J Cell Sci. 2012;125(Pt 22):5467–78. doi:10.1242/jcs.109488.
  Article CAS PubMed Google Scholar
• Sagert J, West J, Wong C, Desnoyers L, Vasiljeva O, Richardson J, et al. Transforming Notch ligands into tumor-antigen targets: a Probody-Drug Conjugate (PDC) targeting Jagged 1 and Jagged 2. AACR Annual Meeting, 2014, Abstract #2665.
• Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol. 2008;26(8):925–32. doi:10.1038/nbt.1480.
  Article CAS PubMed Google Scholar
• Panowksi S, Bhakta S, Raab H, Polakis P, Junutula JR. Site-specific antibody drug conjugates for cancer therapy. mAbs. 2014;6(1):34–45. doi:10.4161/mabs.27022.
  Article PubMed Central PubMed Google Scholar
• Strop P, Liu SH, Dorywalska M, Delaria K, Dushin RG, Tran TT, et al. Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem Biol. 2013;20:161–7.
  Article CAS PubMed Google Scholar
• Thomas J, Yurkovetskiy A, Bodyak N, et al. Polyacetal polymer-based anti-HER2 antibody-drug conjugate employing cysteine bioconjugation through thioether linkage allows a high drug loading of dolastatin-derived payload with excellent pharmacokinetics and potent anti-tumor activity. Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19–23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013; 12(11 Suppl): Abstract nr C238